20 projets européens trouvés
Recherche sur 125080 projets européens
EN COURS
An experimental and bioinformatic toolbox for functional epigenomics and its application to epigenetically making and breaking a cancer cell (EpigenomeProgramming)
Date du début: 1 déc. 2016, Date de fin: 30 nov. 2021,
Epigenetic alterations can be detected in all cancers and in essentially every patient. Despite their prevalence, the concrete functional roles of these alterations are not well understood, for two reasons: First, cancer samples tend to carry many correlated epigenetic alterations, making it difficult to statistically distinguish relevant driver events from those that co-occur for other reasons. S
...
Voir le projet
1
Participant partenaire
EN COURS
Solute carrier proteins as the gates managing chemical access to cells (GameofGates)
Date du début: 1 oct. 2016, Date de fin: 30 sept. 2021,
Chemical exchange between cells and their environment occurs at cellular membranes, the interface where biology meets chemistry. Studying mechanisms of drug resistance, I realized that SoLute Carrier proteins (SLCs), not only represent the major class of small molecule transporters, but that they are encoded by one of the most neglected group of human genes. I identified a case where an SLC contro
...
Voir le projet
1
Participant partenaire
EN COURS
Crosstalk of Metabolism and Inflammation (CMIL)
Date du début: 1 avr. 2016, Date de fin: 31 mars 2021,
Inflammation is a response to noxious stimuli and initiates tissue repair. If resolution fails, however, chronic inflammation develops, which drives tissue damage in many diseases including autoimmunity, cancer and infections. Inflammatory processes are increasingly being appreciated as tightly integrated with metabolic pathways. The molecular crosstalk occurs on different levels including secrete
...
Voir le projet
1
Participant partenaire
TERMINÉ
Leading Innovative measures to reach gender Balance in Research Activities (LIBRA)
Date du début: 1 oct. 2015, Date de fin: 31 mars 2019,
The main goals of LIBRA are to implement innovative Gender Equality Plans (GEPs) that will empower women researchers to achieve successful careers in science, remove gender barriers and biases at an institutional level, and raise awareness of gender aspects in the experimental design of pre-clinical research projects. To achieve these goals we will: 1) conduct an initial external assessment of eac
...
Voir le projet
11
Participants partenaires
TERMINÉ
Inborn errors of innate immunity: systems genomics route to the core of the immune system (ImmunoCore)
Date du début: 1 nov. 2013, Date de fin: 31 oct. 2018,
The ultimate relevance of a component of the innate immune system in human physiology is uncovered by the consequence of mutations in the associated gene. We have integrated systems genomics tools to mine, uncover and pathway-map primary deficiencies with high efficiency. Primary immunodeficiency disorders involving innate immunity are characterized by recurrent and life-threatening infections. Im
...
Voir le projet
1
Participant partenaire
TERMINÉ
Synthetic Lethal Interactions with nucleophosMin 1 (SLIM)
Date du début: 1 juil. 2016, Date de fin: 30 juin 2018,
Less than 25% of patients diagnosed with acute myeloid leukemia (AML) survive longer than 5 years. Current treatment regimen are based on non-specifically acting cytotoxic drugs that cause severe side effects. More effective and more specific, targeted therapies are thus needed. Progress, however, has long been hampered by a lack of understanding of the molecular vulnerabilities of the disease. We
...
Voir le projet
1
Participant partenaire
TERMINÉ
Discovering Gene-Drug Interactions in Breast Cancer With a Systematic and Genetically Tractable Model (GENES, DRUGS AND BREAST CANCER)
Date du début: 1 mai 2013, Date de fin: 30 avr. 2018,
Biomedical research has been very successful in finding the individual genes that are deregulated in cancer and it is estimated that ~2% of all genes can be classified as “cancer genes”. However, it has proven challenging to translate this genomics knowledge into effective treatments.One complication is that cancer cells typically carry many molecular aberrations and every tumor displays a unique
...
Voir le projet
2
Participants partenaires
TERMINÉ
Chemical Hematology: breaking resistance of hematological malignancies through personalized drug trials (chemos)
Date du début: 1 oct. 2016, Date de fin: 30 sept. 2017,
Personalized medicine aspires to provide optimal therapy in real-time during patient treatment, however current methodology falls short to deliver this in a robust manner. With this in mind, we invented a method for the screening of thousands of drug responses in small samples of an individual’s peripheral blood by automated microscopy and single-cell image analysis. We termed this method pharmaco
...
Voir le projet
1
Participant partenaire
TERMINÉ
BERG – Biomedical Epigenomics Research Group (BERG)
Date du début: 1 juil. 2013, Date de fin: 30 juin 2017,
Significance: The genetic code of the DNA provides a universal building plan for the cell’s molecular machinery. But a second code is needed to control the complexity of the human body, organizing 100 billion cells with identical genomes into 200 specialized cell types. This second code is called “epigenetic”. Defects in the epigenetic code play an important role in cancer, and they create an oppo
...
Voir le projet
1
Participant partenaire
TERMINÉ
Solute carrier proteins and the uptake of cytotoxic approved drugs (DrugsUP)
Date du début: 1 mai 2015, Date de fin: 30 avr. 2017,
...
underestimated in its importance. To test this hypothesis, the study proposed here aims at identifying SLC transporters involved in the uptake of a well-characterized set of commercialized drugs. The CeMM Library Of Unique Drugs (CLOUD) is a library of 300 compounds selected to be representative of the chemical space covered by all commercially available drugs. Human cell lines carrying deletions
...
Voir le projet
1
Participant partenaire
TERMINÉ
A BLUEPRINT of Haematopoietic Epigenomes (BLUEPRINT)
Date du début: 1 oct. 2011, Date de fin: 30 sept. 2016,
In response to the call for a high impact initiative on the human epigenome, the BLUEPRINT Consortium has been formed with the aim of generating at least 100 reference epigenomes and studying them to advance and exploit knowledge of the underlying biological processes and mechanisms in health and disease. BLUEPRINT will focus on distinct types of haematopoietic cells from healthy individuals and o
...
Voir le projet
45
Participants partenaires
TERMINÉ
DNA damage response: ATMIN regulated non-canonical ATM activation (NONCANATM)
Date du début: 1 sept. 2012, Date de fin: 31 août 2016,
The checkpoint kinase ATM (Ataxia Telangiectasia Mutated) transduces genomic stress signals to halt cell cycle progression and promote DNA repair in response to DNA damage. ATMIN (for ATM INteractor) is a cofactor for ATM that shares functional homologies with another cofactor, NBS1. Whereas NBS1 is required for ATM function after induction of double-stand breaks (DSBs), ATMIN is essential for ATM
...
Voir le projet
1
Participant partenaire
TERMINÉ
ASSET: Analysing and Striking the Sensitivities of Embryonal Tumours (ASSET)
Date du début: 1 nov. 2010, Date de fin: 30 avr. 2016,
Cancer is hallmarked by multiple genetic aberrations that lead to a functional derangement of cellular signalling networks. Embryonal tumours (ETs) comprising neuroblastoma, medulloblastoma and Ewing sarcoma, occur early in life, and thus may reveal pathogenetically relevant lesions clearer than adulthood tumours which carry passenger mutations accumulated during life. ASSET will exploit this fact
...
Voir le projet
20
Participants partenaires
TERMINÉ
A proteomic screen to identify cytoplasmic DNA sensor proteins mediating type I Interferon production (INNATEDNASENSOR)
Date du début: 20 déc. 2013, Date de fin: 19 déc. 2015,
Detection of pathogens by the innate immune system depends on the recognition of microbial components by dedicated receptors. During viral and bacterial infections, pathogen-derived nucleic acids are recognized by innate receptors resulting in the production of type I IFNs and inflammatory cytokines. While it is established that cytoplasmic delivery of viral, bacterial and even host DNA triggers t
...
Voir le projet
1
Participant partenaire
TERMINÉ
Systematic Identification and Validation of Epigenetic Cancer Lesions by Chemical Biology and Functional Genomics (EPICAL)
Date du début: 1 déc. 2011, Date de fin: 30 nov. 2015,
...
ies and small molecule probes. This project directly benefits from the experience at the Broad Institute, where Stefan Kubicek worked for 3.5 years, which allowed him to bring to CeMM a library of knock-down constructs targeting all chromatin proteins in collaboration with the Broad RNAi platform. Similarly, his work on histone demethylases has yielded interesting probe compounds, and his continu
...
Voir le projet
1
Participant partenaire
TERMINÉ
HEMatopoietic cell IDentity : genetic and epigenetic regulation in normal and malignant hematopoiesis (HEM_ID)
Date du début: 1 nov. 2011, Date de fin: 31 oct. 2015,
In hematopoiesis, failure to maintain homeostasis and regenerative functions result in a multitude of hematological malignancies, including myelodysplastic syndromes, lymphomas and leukemias, that represent a medical challenge and a large socioeconomic burden because of the large number of affected patients of all age groups. Although hierarchical organization of the hematopoietic system has been
...
Voir le projet
12
Participants partenaires
TERMINÉ
European Infrastructure of Open Screening Platforms for Chemical Biology (EU-OPENSCREEN)
Date du début: 1 nov. 2010, Date de fin: 30 avr. 2015,
The EU-OPENSCREEN Preparatory Phase forms the basis for the construction and operation of a pan-European infrastructure of open screening platforms for Chemical Biology. EU-OPENSCREEN will bring together leading laboratories from 14 European countries covering all aspects of Chemical Biology from high-throughput screening with a dedicated compound library to assay development, chemical synthesis f
...
Voir le projet
24
Participants partenaires
TERMINÉ
Acute Inflammation Resolution by Soluble Human Inhibitory Protein (AIRSHIP)
Date du début: 1 déc. 2012, Date de fin: 30 nov. 2013,
"Acute inflammatory processes are associated with infections as well as autoimmune flares at the basis of a variety of human diseases. While the molecular components and the logic of pro-inflammatory program are relatively well understood, less is known about the molecular mechanism of resolution, governing the termination of inflammatory responses. In the course of carrying out the i-FIVE ERC gra
...
Voir le projet
1
Participant partenaire
TERMINÉ
"Small Molecule Antagonists of chromatin modifying enzymes for Regulation of Transcription, proliferation and differentiation" (SMART)
Date du début: 1 août 2008, Date de fin: 31 juil. 2011,
"Chromatin modifying enzymes play important roles in the regulation of gene expression, the establishment and maintenance of distinct cell types during development and the control of cellular proliferation. All of these features make them interesting targets for small molecule inhibitors that can function as probes for basic biological questions but also as lead compounds for drug development. Ind
...
Voir le projet
1
Participant partenaire
TERMINÉ
Dissecting pathogen recognition complexes of Toll-like receptors: hunting for new co-receptors and ligands (TolLiCoR)
Date du début: 1 août 2008, Date de fin: 31 juil. 2010,
Toll-like receptors (TLRs) are trans-membrane proteins that recognize pathogen associated molecular patterns (PAMPs) and subsequently induce an intracellular signaling cascade that triggers the activation of transcription factors which initiate the expression of host defense proteins. Ten human, structurally highly conserved TLRs have been identified and assigned to structurally very dissimilar li
...
Voir le projet